Emerald Advisers LLC Sells 15,622 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Emerald Advisers LLC reduced its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 811,680 shares of the specialty pharmaceutical company's stock after selling 15,622 shares during the quarter. Emerald Advisers LLC owned 2.52% of Collegium Pharmaceutical worth $23,255,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in COLL. KLP Kapitalforvaltning AS acquired a new position in Collegium Pharmaceutical during the 4th quarter valued at about $736,000. Hillsdale Investment Management Inc. lifted its holdings in shares of Collegium Pharmaceutical by 1.0% in the fourth quarter. Hillsdale Investment Management Inc. now owns 116,200 shares of the specialty pharmaceutical company's stock valued at $3,329,000 after purchasing an additional 1,100 shares in the last quarter. Summit Global Investments bought a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $232,000. Teacher Retirement System of Texas boosted its position in shares of Collegium Pharmaceutical by 16.6% during the fourth quarter. Teacher Retirement System of Texas now owns 9,568 shares of the specialty pharmaceutical company's stock valued at $274,000 after buying an additional 1,363 shares during the last quarter. Finally, Intech Investment Management LLC grew its holdings in Collegium Pharmaceutical by 593.7% during the fourth quarter. Intech Investment Management LLC now owns 67,132 shares of the specialty pharmaceutical company's stock worth $1,923,000 after buying an additional 57,455 shares in the last quarter.

Remove Ads

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares in the company, valued at $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Colleen Tupper sold 1,949 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now directly owns 177,195 shares of the company's stock, valued at approximately $5,315,850. This represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 109,193 shares of company stock valued at $3,243,594. Company insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Price Performance

Shares of COLL traded down $0.40 during midday trading on Thursday, hitting $29.56. 354,946 shares of the company traded hands, compared to its average volume of 418,330. Collegium Pharmaceutical, Inc. has a one year low of $27.28 and a one year high of $42.29. The firm has a market cap of $930.73 million, a P/E ratio of 12.74 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a 50-day moving average of $30.43 and a 200-day moving average of $32.50.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on COLL. Piper Sandler dropped their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a research report on Friday, January 10th. Finally, HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.